APA aipamena

Tarhini, A. A., Leng, S., Moschos, S. J., Yin, Y., Sander, C., Lin, Y., . . . Kirkwood, J. M. (2012). Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Chicago Style aipamena

Tarhini, Ahmad A., Siyang Leng, Stergios J. Moschos, Yan Yin, Cindy Sander, Yan Lin, William E. Gooding, and John M. Kirkwood. Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27L), Gp100 (209-217, 210M), and Tyrosinase (368-376, 370D) In-adjuvant With PF-3512676 and GM-CSF in Metastatic Melanoma. 2012.

MLA aipamena

Tarhini, Ahmad A., et al. Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27L), Gp100 (209-217, 210M), and Tyrosinase (368-376, 370D) In-adjuvant With PF-3512676 and GM-CSF in Metastatic Melanoma. 2012.